Cerenome (PSTV) Liabilities and Shareholders Equity (2010 - 2026)

Plus Therapeutics (PSTV) has reported Liabilities and Shareholders Equity for 17 consecutive years, with $19.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 65.2% year-over-year to $19.9 million; the TTM figure through Mar 2026 stood at $65.3 million (up 76.96% YoY), while the FY2025 annual figure was $16.3 million, up 146.12% from the prior year.
• Liabilities and Shareholders Equity improved to $19.9 million in Q1 2026 per PSTV's latest filing, from $16.3 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $24.5 million in Q1 2022 and bottomed at $5.6 million in Q1 2024.
• Historically, Liabilities and Shareholders Equity has averaged $15.0 million across 5 years, with a median of $14.2 million in 2023.
• Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity sank 64.06% — and 2025, when it soared 167.56%.
• Plus Therapeutics' Liabilities and Shareholders Equity stood at $23.9 million in 2022, then plunged by 52.29% to $11.4 million in 2023, then slumped by 41.75% to $6.6 million in 2024, then jumped by 146.12% to $16.3 million in 2025, then climbed by 22.0% to $19.9 million in 2026.
• Business Quant data shows PSTV's Liabilities and Shareholders Equity at $19.9 million in Q1 2026, $16.3 million in Q4 2025, and $18.7 million in Q3 2025.